Limits...
Increased serum TRAIL and DR5 levels correlated with lung function and inflammation in stable COPD patients.

Wu Y, Shen Y, Zhang J, Wan C, Wang T, Xu D, Yang T, Wen F - Int J Chron Obstruct Pulmon Dis (2015)

Bottom Line: Several studies have suggested that tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and its receptors were not only involved in diseases associated with apoptosis but also in inflammatory diseases.Serum levels of TRAIL, decoy receptor 5 (DR5), C-reactive protein, and tumor necrosis factor-α were analyzed using multiplex enzyme-linked immunosorbent assay kits.Mean levels of serum TRAIL and DR5 were significantly higher in COPD patients than those in controls (50.17±17.70 versus 42.09±15.49 pg/mL, P=0.029; 48.15±22.88 versus 38.94±10.95 pg/mL, P=0.032, respectively).

View Article: PubMed Central - PubMed

Affiliation: Department of Respiratory and Critical Care Medicine, West China Hospital of Sichuan University, Chengdu, Sichuan, People's Republic of China ; Division of Pulmonary Diseases, State Key Laboratory of Biotherapy of China, Chengdu, Sichuan, People's Republic of China.

ABSTRACT

Background: Chronic obstructive pulmonary disease (COPD) is associated with abnormal systemic inflammation, and apoptosis is one of the pathogenic mechanisms of COPD. Several studies have suggested that tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and its receptors were not only involved in diseases associated with apoptosis but also in inflammatory diseases. However, limited data about the possible relationship between COPD and TRAIL/TRAIL-receptors are available.

Objective: To evaluate the potential relationship between TRAIL/TRAIL-receptors and COPD.

Methods: Serum levels of TRAIL, decoy receptor 5 (DR5), C-reactive protein, and tumor necrosis factor-α were analyzed using multiplex enzyme-linked immunosorbent assay kits. Then, serum levels of TRAIL and DR5 in 57 COPD patients with 35 healthy controls were compared and correlated with lung function and systemic inflammation.

Results: Mean levels of serum TRAIL and DR5 were significantly higher in COPD patients than those in controls (50.17±17.70 versus 42.09±15.49 pg/mL, P=0.029; 48.15±22.88 versus 38.94±10.95 pg/mL, P=0.032, respectively). Serum levels of TRAIL and DR5 correlated inversely with forced expiratory volume in 1 second % predicted, an index of lung function in COPD (r=-0.354, P=0.007 for TRAIL; r=-0.394, P=0.002 for DR5) in all participants (r=-0.291, P=0.005 for TRAIL; r=-0.315, P=0.002 for DR5), while DR5 correlated positively with C-reactive protein (r=0.240, P=0.021 for total subjects) and TRAIL correlated positively with tumor necrosis factor-α (r=0.371, P=0.005 for COPD; r=0.349, P=0.001 for total subjects).

Conclusion: Our results suggested that circulating TRAIL and DR5 increased in COPD patients and were associated with lung function and systemic inflammation in COPD. Future studies are needed to verify whether and how TRAIL and its receptors play roles in COPD.

No MeSH data available.


Related in: MedlinePlus

TraIl and DR5 were correlated with pulmonary function.Notes: TraIl in the serum was inversely correlated with (A) FEV1% predicted (r=−0.354, P=0.007 for COPD; r=−0.291, P=0.005 for all participants) and (B) FEV1/FVC (r=−0.32, P=0.013 for COPD; r=−0.321, P=0.002 for all participants). DR5 was inversely correlated with (C) FEV1% predicted (r=−0.394, P=0.002 for COPD; r=−0.315, P=0.002 for total subjects) and (D) FEV1/FVC (r=−0.316, P=0.017 for COPD; r=−0.358, P=0.000 for total subjects). DR5 was log transformed in the statistical analyses. The orange solid line denotes the line of best fit in COPD, the blue line represents the line of best fit in all subjects, and Pearson’s correlation coefficient is presented as an r-value.Abbreviations: COPD, chronic obstructive pulmonary disease; DR5, decoy receptor 5; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; TRAIL, tumor necrosis factor-related apoptosis-inducing ligand.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4644161&req=5

f3-copd-10-2405: TraIl and DR5 were correlated with pulmonary function.Notes: TraIl in the serum was inversely correlated with (A) FEV1% predicted (r=−0.354, P=0.007 for COPD; r=−0.291, P=0.005 for all participants) and (B) FEV1/FVC (r=−0.32, P=0.013 for COPD; r=−0.321, P=0.002 for all participants). DR5 was inversely correlated with (C) FEV1% predicted (r=−0.394, P=0.002 for COPD; r=−0.315, P=0.002 for total subjects) and (D) FEV1/FVC (r=−0.316, P=0.017 for COPD; r=−0.358, P=0.000 for total subjects). DR5 was log transformed in the statistical analyses. The orange solid line denotes the line of best fit in COPD, the blue line represents the line of best fit in all subjects, and Pearson’s correlation coefficient is presented as an r-value.Abbreviations: COPD, chronic obstructive pulmonary disease; DR5, decoy receptor 5; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; TRAIL, tumor necrosis factor-related apoptosis-inducing ligand.

Mentions: We analyzed the correlations of TRAIL and DR5 with FEV1% predicted, FEV1/FVC, CRP, and TNF-α in COPD patients and in all subjects, and found that TRAIL was inversely correlated with FEV1% predicted (r=−0.354, P=0.007, Figure 3A) and FEV1/FVC (r=−0.32, P=0.013, Figure 3B) in COPD. Similar results were also found in all participants (r=−0.291, P=0.005; r=−0321, P=0.002; respectively, Figure 3A and B). We also observed that DR5 had a negative correlation with FEV1% predicted (r=−0.394, P=0.002 for COPD; r=−0.315, P=0.002 for total subjects, Figure 3C) and FEV1/FVC (r=−0.316, P=0.017 for COPD; r=−0.358, P=0.000 for subjects, Figure 3D). More importantly, we still found a positive relationship between TRAIL and TNF-α in COPD and in all subjects (r=0.371, P=0.005; r=0.349, P=0.001, respectively; Figure 4A) and a positive correlation between DR5 and CRP in subjects (r=0.240, P=0.021, Figure 4B). All these correlations are shown in the Tables 3 and 4.


Increased serum TRAIL and DR5 levels correlated with lung function and inflammation in stable COPD patients.

Wu Y, Shen Y, Zhang J, Wan C, Wang T, Xu D, Yang T, Wen F - Int J Chron Obstruct Pulmon Dis (2015)

TraIl and DR5 were correlated with pulmonary function.Notes: TraIl in the serum was inversely correlated with (A) FEV1% predicted (r=−0.354, P=0.007 for COPD; r=−0.291, P=0.005 for all participants) and (B) FEV1/FVC (r=−0.32, P=0.013 for COPD; r=−0.321, P=0.002 for all participants). DR5 was inversely correlated with (C) FEV1% predicted (r=−0.394, P=0.002 for COPD; r=−0.315, P=0.002 for total subjects) and (D) FEV1/FVC (r=−0.316, P=0.017 for COPD; r=−0.358, P=0.000 for total subjects). DR5 was log transformed in the statistical analyses. The orange solid line denotes the line of best fit in COPD, the blue line represents the line of best fit in all subjects, and Pearson’s correlation coefficient is presented as an r-value.Abbreviations: COPD, chronic obstructive pulmonary disease; DR5, decoy receptor 5; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; TRAIL, tumor necrosis factor-related apoptosis-inducing ligand.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4644161&req=5

f3-copd-10-2405: TraIl and DR5 were correlated with pulmonary function.Notes: TraIl in the serum was inversely correlated with (A) FEV1% predicted (r=−0.354, P=0.007 for COPD; r=−0.291, P=0.005 for all participants) and (B) FEV1/FVC (r=−0.32, P=0.013 for COPD; r=−0.321, P=0.002 for all participants). DR5 was inversely correlated with (C) FEV1% predicted (r=−0.394, P=0.002 for COPD; r=−0.315, P=0.002 for total subjects) and (D) FEV1/FVC (r=−0.316, P=0.017 for COPD; r=−0.358, P=0.000 for total subjects). DR5 was log transformed in the statistical analyses. The orange solid line denotes the line of best fit in COPD, the blue line represents the line of best fit in all subjects, and Pearson’s correlation coefficient is presented as an r-value.Abbreviations: COPD, chronic obstructive pulmonary disease; DR5, decoy receptor 5; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; TRAIL, tumor necrosis factor-related apoptosis-inducing ligand.
Mentions: We analyzed the correlations of TRAIL and DR5 with FEV1% predicted, FEV1/FVC, CRP, and TNF-α in COPD patients and in all subjects, and found that TRAIL was inversely correlated with FEV1% predicted (r=−0.354, P=0.007, Figure 3A) and FEV1/FVC (r=−0.32, P=0.013, Figure 3B) in COPD. Similar results were also found in all participants (r=−0.291, P=0.005; r=−0321, P=0.002; respectively, Figure 3A and B). We also observed that DR5 had a negative correlation with FEV1% predicted (r=−0.394, P=0.002 for COPD; r=−0.315, P=0.002 for total subjects, Figure 3C) and FEV1/FVC (r=−0.316, P=0.017 for COPD; r=−0.358, P=0.000 for subjects, Figure 3D). More importantly, we still found a positive relationship between TRAIL and TNF-α in COPD and in all subjects (r=0.371, P=0.005; r=0.349, P=0.001, respectively; Figure 4A) and a positive correlation between DR5 and CRP in subjects (r=0.240, P=0.021, Figure 4B). All these correlations are shown in the Tables 3 and 4.

Bottom Line: Several studies have suggested that tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and its receptors were not only involved in diseases associated with apoptosis but also in inflammatory diseases.Serum levels of TRAIL, decoy receptor 5 (DR5), C-reactive protein, and tumor necrosis factor-α were analyzed using multiplex enzyme-linked immunosorbent assay kits.Mean levels of serum TRAIL and DR5 were significantly higher in COPD patients than those in controls (50.17±17.70 versus 42.09±15.49 pg/mL, P=0.029; 48.15±22.88 versus 38.94±10.95 pg/mL, P=0.032, respectively).

View Article: PubMed Central - PubMed

Affiliation: Department of Respiratory and Critical Care Medicine, West China Hospital of Sichuan University, Chengdu, Sichuan, People's Republic of China ; Division of Pulmonary Diseases, State Key Laboratory of Biotherapy of China, Chengdu, Sichuan, People's Republic of China.

ABSTRACT

Background: Chronic obstructive pulmonary disease (COPD) is associated with abnormal systemic inflammation, and apoptosis is one of the pathogenic mechanisms of COPD. Several studies have suggested that tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and its receptors were not only involved in diseases associated with apoptosis but also in inflammatory diseases. However, limited data about the possible relationship between COPD and TRAIL/TRAIL-receptors are available.

Objective: To evaluate the potential relationship between TRAIL/TRAIL-receptors and COPD.

Methods: Serum levels of TRAIL, decoy receptor 5 (DR5), C-reactive protein, and tumor necrosis factor-α were analyzed using multiplex enzyme-linked immunosorbent assay kits. Then, serum levels of TRAIL and DR5 in 57 COPD patients with 35 healthy controls were compared and correlated with lung function and systemic inflammation.

Results: Mean levels of serum TRAIL and DR5 were significantly higher in COPD patients than those in controls (50.17±17.70 versus 42.09±15.49 pg/mL, P=0.029; 48.15±22.88 versus 38.94±10.95 pg/mL, P=0.032, respectively). Serum levels of TRAIL and DR5 correlated inversely with forced expiratory volume in 1 second % predicted, an index of lung function in COPD (r=-0.354, P=0.007 for TRAIL; r=-0.394, P=0.002 for DR5) in all participants (r=-0.291, P=0.005 for TRAIL; r=-0.315, P=0.002 for DR5), while DR5 correlated positively with C-reactive protein (r=0.240, P=0.021 for total subjects) and TRAIL correlated positively with tumor necrosis factor-α (r=0.371, P=0.005 for COPD; r=0.349, P=0.001 for total subjects).

Conclusion: Our results suggested that circulating TRAIL and DR5 increased in COPD patients and were associated with lung function and systemic inflammation in COPD. Future studies are needed to verify whether and how TRAIL and its receptors play roles in COPD.

No MeSH data available.


Related in: MedlinePlus